TERF2 Antibody | 7727

TERF2 Antibody | 7727 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Mouse: (92%)

Immunogen: TERF2 antibody was raised against a 17 amino acid peptide near the amino terminus of human TERF2.
The immunogen is located within the first 50 amino acids of TERF2.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB, IHC-P

Application: TERF2 antibody can be used for detection of TERF2 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.

Specificiy: TERF2 antibody is human specific.

Positive Control 1: Cat. No. 1210 - HEK293 Cell Lysate

Positive Control 2: Cat. No. 10-401 - Human Kidney Tissue Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 60 kDa
Observed: 69 kDa

Validation: N/A

Isoform: N/A

Purification: TERF2 antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TERF2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: TERF2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

Alternate Name: TERF2 Antibody: TRF2, TRBF2, TRF2, Telomeric repeat-binding factor 2, TTAGGG repeat-binding factor 2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The telomeric repeat binding factor family (TERF1 and TERF2) plays a key role in cellular immortalization and cellular senescence (1) . TERF2, as a component of the telomere nucleoprotein complex, is present at telomeres in metaphase of the cell cycle (2) . TERF2 is a second negative regulator of telomere length and binds as a dimer to TTAGGG repeats at ends of chromosomes (telomeres) , where it blocks inappropriate activation of the ATM/p53 pathway (2, 3) . TERF1 negatively regulates telomere elongation, while TERF2 protects the chromosome ends by inhibiting end-to-end fusions. Down-regulation of TRF expression in tumor cells may contribute to cell immortalization and malignant progression (4, 5) .